Crossmark Global Holdings, Inc. Alkermes Plc. Transaction History
Crossmark Global Holdings, Inc.
- $6.5 Billion
- Q3 2025
A detailed history of Crossmark Global Holdings, Inc. transactions in Alkermes Plc. stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 10,890 shares of ALKS stock, worth $316,245. This represents 0.01% of its overall portfolio holdings.
Number of Shares
10,890
Previous 10,840
0.46%
Holding current value
$316,245
Previous $310,000
5.16%
% of portfolio
0.01%
Previous 0.01%
Shares
14 transactions
Others Institutions Holding ALKS
# of Institutions
404Shares Held
176MCall Options Held
901KPut Options Held
400K-
Black Rock Inc. New York, NY29.1MShares$845 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.2MShares$528 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10.2MShares$297 Million0.03% of portfolio
-
State Street Corp Boston, MA8.54MShares$248 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY8.09MShares$235 Million1.98% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $4.77B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...